20. The DEFER Study: Design Prospective randomized multicentric trial (14 centers) in 325 patients with stable chest pain and an intermediate stenosis without objective evidence of ischemia Aalst Amsterdam Eindhoven Essen Gothenborg Hamburg Liège Maastricht Madrid Osaka Rotterdam Seoul Utrecht Zwolle data collection & analysis: Jan Willem Bech, MD, PhD Pepijn van Schaardenburgh, MD
21.
22. DEFER Group REFERENCE Group PERFORM Group Patients scheduled for PCI without Proof of Ischemia (n=325) performance of PTCA (158) FFR 0.75 (91) No PTCA FFR 0.75 (90) PTCA FFR < 0.75 (76) PTCA Randomization deferral of PTCA (167) FFR < 0.75 (68) PTCA
23. The DEFER Study: Baseline data Randomized to Randomized to Deferral of PTCA Performance of PTCA N=167 N=158 Age, (yr) 62 9 63 10 Female sex (%) 29 29 Ejection Fraction (%) 67 10 68 9 Diabetes (%) 13 12 Hypertension (%) 41 35 Hyperlipidemia (%) 47 48 Current Smoker (%) 30 25 Family History CAD (%) 50 49
24. 78.8 72.7 64.4 0 1 2 3 4 5 0 25 50 75 100 Defer Perform Reference (FFR < 0.75) p=0.52 p=0.17 p=0.03 Years of Follow-up event – free survival (%) 88 90 96 103 105 135 Reference gr 65 67 70 73 78 88 Perform group 72 73 74 82 85 90 Defer group No. at risk
25. Cardiac Death And Acute MI After 5 Years 3.3 7.9 15.7 0 5 10 15 20 % P=0.20 P< 0.03 P< 0.005 DEFER PERFORM REFERENCE FFR > 0.75 FFR < 0.75